专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

EP2349210A2 PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS 有权
标题翻译：方法和组合物脂质体和高效地摄食基因沉默疗法
公开(公告)号：EP2349210A2
公开(公告)日：2011-08-03
申请号：EP09744527.4
申请日：2009-10-16
申请人： Marina Biotech, Inc.
发明人： POLISKY, Barry, A. , ADAMI, Roger, C. , TEMPLIN, Michael, V. , HARVIE, Pierrot , JOHNS, Rachel, E. , GIYANANI, Jaya, S. , HOUSTON, Michael, E.
IPC分类号： A61K9/127 , A61K48/00 , C12N15/11 , C12N15/88
CPC分类号： A61K9/127 , A61K9/1271 , A61K9/1277 , C12N15/111 , C12N15/113 , C12N15/88 , C12N2310/14 , C12N2320/32
摘要： Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition. An efficiency for delivering a drug cargo is provided. Compositions can include a liposome containing one or more carrier particles, each carrier particle having an active agent and a peptide, wherein the ratio of the mass of the peptide plus the mass of the liposome to the mass of the active agent is less than about 15.

12. 发明公开

EP2277508A1 Emulation of lipoprotein structures 无效
标题翻译： Nachahmung von Lipoproteinstrukturen
公开(公告)号：EP2277508A1
公开(公告)日：2011-01-26
申请号：EP09165106.7
申请日：2009-07-09
申请人： Marina Biotech, Inc.
发明人： Panzner, Steffen , Siepi, Evgenios
IPC分类号： A61K9/127 , A61K9/133 , A61K48/00
CPC分类号： A61K9/0048 , A61K9/0051 , A61K9/1272 , A61K48/0025 , C12N15/111 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/3515 , C12N2320/32
摘要： The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are guanido groups, and their use for serum resistant transfection of cells.
摘要翻译：本发明涉及脂质组合物，脂质体具有包含阴离子和阳离子部分的混合物的外表面; 其中阳离子部分的至少一部分是胍基，以及它们用于细胞抗血清转染的用途。

13. 发明公开

EP3434259A1 AMINO ACID LIPIDS AND USES THEREOF 审中-公开
公开(公告)号：EP3434259A1
公开(公告)日：2019-01-30
申请号：EP18178105.5
申请日：2008-05-02
申请人： Marina Biotech, Inc.
发明人： QUAY, Steven , HOUSTON, Michael , HARVIE, Pierrot , ADAMI, Roger , FAM, Renata , PRIEVE, Mary , FOSNAUGH, Kathy , SETH, Shaguna
IPC分类号： A61K9/127
摘要： The present invention provides a compound comprising the structure shown in Formula I for use in delivering a therapeutic nucleic acid, one or more drug agents, or a biologically active agent to a cell,

R 3 -(C=O)-Xaa-Z-R 4 Formula I

wherein
Xaa is histidine, 1-methylhistidine, pyridylalanine, lysine, arginine, homoarginine, nor-norarginine, ornithine, homolysine, asparagine, N ethylasparagine, glutamine, 4-aminophenylalanine, and nor-arginine, or an N-methylated version thereof;
R 3 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl;
R 4 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl;
wherein both R 3 and R 4 are lipophilic tails; and
Z is NH, O, S, -CH 2 S-, -CH 2 S(O)-, or an organic linker consisting of 1-40 atoms selected from hydrogen, carbon, oxygen, nitrogen, and sulfur atoms;
and salts thereof.

14. 发明授权

EP2349210B1 PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS 有权
标题翻译：方法和组合物脂质体和高效地摄食基因沉默疗法
公开(公告)号：EP2349210B1
公开(公告)日：2015-03-18
申请号：EP09744527.4
申请日：2009-10-16
申请人： Marina Biotech, Inc.
发明人： POLISKY, Barry, A. , ADAMI, Roger, C. , TEMPLIN, Michael, V. , HARVIE, Pierrot , JOHNS, Rachel, E. , GIYANANI, Jaya, S. , HOUSTON, Michael, E.
IPC分类号： A61K9/127 , A61K48/00 , C12N15/11 , C12N15/88
CPC分类号： A61K9/127 , A61K9/1271 , A61K9/1277 , C12N15/111 , C12N15/113 , C12N15/88 , C12N2310/14 , C12N2320/32

15. 发明授权

EP2157982B1 AMINO ACID LIPIDS AND USES THEREOF 有权
标题翻译：氨基血脂和用途
公开(公告)号：EP2157982B1
公开(公告)日：2014-12-17
申请号：EP08747568.7
申请日：2008-05-02
申请人： Marina Biotech, Inc.
发明人： QUAY, Steven, C. , HOUSTON, Michael, E. , HARVIE, Pierrot , ADAMI, Roger, C. , FAM, Renata , PRIEVE, Mary, G. , FOSNAUGH, Kathy, L. , SETH, Shaguna
IPC分类号： A61K48/00 , A61K47/06
CPC分类号： A61K47/183 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/7088 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/44 , A61K48/0025 , A61K48/0033 , C07C235/02 , C07C279/12 , C07C279/14 , C07D213/40 , C07D213/56 , C07D233/26 , C07D233/64 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N15/1138 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y10S514/943
摘要： The present invention provides a compound comprising the structure shown in Formula I for use in delivering a therapeutic nucleic acid, one or more drug agents, or a biologically active agent to a cell, €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ R 3 -(C=O)-Xaa-Z-R 4 €ƒ€ƒ€ƒ€ƒ€ƒFormula I wherein Xaa is histidine, 1-methylhistidine, pyridylalanine, lysine, arginine, homoarginine, nor-norarginine, ornithine, homolysine, asparagine, N ethylasparagine, glutamine, 4-aminophenylalanine, and nor-arginine, or an N-methylated version thereof; R 3 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl; R 4 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl; wherein both R 3 and R 4 are lipophilic tails; and Z is NH, O, S, -CH 2 S-, -CH 2 S(O)-, or an organic linker consisting of 1-40 atoms selected from hydrogen, carbon, oxygen, nitrogen, and sulfur atoms; and salts thereof.

16. 发明公开

EP2563922A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF 审中-公开
标题翻译： NUKLEINSÄUREVERBINDUNGENMITKONFORMATIONSEINGESCHRÄNKTENMONOMEREN UND IHRE VERWENDUNG
公开(公告)号：EP2563922A1
公开(公告)日：2013-03-06
申请号：EP11717901.0
申请日：2011-04-26
申请人： Marina Biotech, Inc.
发明人： VAISH, Narendra, K. , FOSNAUGH,Kathy, L. , SETH, Shaguna , HOUSTON JR., Michael, E. , TEMPLIN, Michael, V.
IPC分类号： C12N15/113 , A61P35/00
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/3231 , C12N2310/533 , C12N2320/30 , C12N2320/51 , C12Y103/99005 , C12Y203/0102 , C12Y207/01153 , C12Y207/11001 , C12Y207/11021 , C12Y207/11024 , C12Y304/21021
摘要： This disclosure provides single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that regulate the function or expression of nucleic acid molecules expressed in a cell or a cell regulatory system dependent upon a nucleic acid. The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). Certain nucleic acid compounds may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (UNA). The nucleic acid compounds are useful in various therapeutic modalities.
摘要翻译：本公开提供具有调节在细胞中表达的核酸分子的功能或表达的一个或多个双链区域的单链和多链核酸化合物或依赖于核酸的细胞调节系统。本公开提供了一系列具有一个或多个构象限制性核单体（CRN）的核酸化合物。某些核酸化合物可以具有一个或多个构象限制的核单体和一个或多个羟甲基取代的核单体（UNA）。核酸化合物可用于各种治疗方式。

17. 发明公开

EP2471920A3 Nucleic acid compounds for inhibiting WNT gene expression and uses thereof 审中-公开
标题翻译：核酸化合物抑制Wnt基因的表达及其应用
公开(公告)号：EP2471920A3
公开(公告)日：2012-10-10
申请号：EP12153915.9
申请日：2008-03-03
申请人： Marina Biotech, Inc.
发明人： Quay, Steven C. , McSwiggen, James , Vaish, Narendra K. , Ahmadian, Mohammed
IPC分类号： C12N15/11 , A61K31/713
CPC分类号： C12N15/1135 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.

18. 发明公开

EP2471920A2 Nucleic acid compounds for inhibiting WNT gene expression and uses thereof 审中-公开
标题翻译：核酸化合物抑制Wnt基因的表达及其应用
公开(公告)号：EP2471920A2
公开(公告)日：2012-07-04
申请号：EP12153915.9
申请日：2008-03-03
申请人： Marina Biotech, Inc.
发明人： Quay, Steven C. , McSwiggen, James , Vaish, Narendra K. , Ahmadian, Mohammed
IPC分类号： C12N15/11 , A61K31/713
CPC分类号： C12N15/1135 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.
摘要翻译：本公开提供meroduplex核糖核酸分子（MDRNA）能够减少或沉默WNT1，WNT2，或Wnt3a的基因的表达。在本公开的MDRNA包括至少三股没有结合以形成由切口或缺口分开的至少两个非重叠的双链区worin一个海滩是互补的WNT1，WNT2，或Wnt3a的mRNA的表达。另外，也可以meroduplex具有至少一个尿苷是5-甲基尿苷，核苷是锁核酸，或任选其它修改，以及它们的任何组合。这样提供了一个降低WNT1，WNT2，或Wnt3a的基因的表达在细胞中或在受试者中以治疗WNT1，WNT2，或Wnt3a的相关疾病的方法。

19. 发明公开

EP2356235A1 E. COLI MEDIATED GENE SILENCING OF BETA-CATENIN 审中-公开
标题翻译：大肠杆菌SWITCHED根沉默β-联蛋白的
公开(公告)号：EP2356235A1
公开(公告)日：2011-08-17
申请号：EP09760660.2
申请日：2009-11-13
申请人： Marina Biotech, Inc.
发明人： FRUEHAUF, Johannes, Heinrich , VAZE, Moreswhar, Bhanudas , LAROUX, Floyd, Stephen , SEXTON, Jessica, Ann , BOLDUC, Gilles, Remeo
IPC分类号： C12N15/113 , C12N15/72 , C12N1/21 , C12R1/19
CPC分类号： C12N15/1135 , C12N1/36 , C12N9/22 , C12N15/111 , C12N15/72 , C12N2310/14 , C12N2310/531 , C12N2320/32
摘要： Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

20. 发明授权

EP2451440B2 AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS 有权转让
标题翻译：包含IMINO脂质体的两性脂质体
公开(公告)号：EP2451440B2
公开(公告)日：2018-03-14
申请号：EP10734065.5
申请日：2010-07-02
申请人： Marina Biotech, Inc.
发明人： PANZNER, Steffen , SIEPI, Evgenios
IPC分类号： A61K9/127 , A61K9/133 , A61K48/00
CPC分类号： A61K9/1272 , C07C233/36 , C07C233/43 , C07C237/22 , C07C279/12 , C07C279/14 , C07D213/75 , C07D233/61 , C07J41/0055 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y02P20/582
摘要： The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charges under physiological conditions, and their use for serum resistant transfection of cells.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式